Zydus Cadila gets USFDA's final nod for fungal treatment drug

New Delhi: Drug firm Zydus Cadila has received final approval from the US health regulator to market Voriconazole tablets, used to treat fungal infections, in the American market.

The Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Voriconazole tablets in strengths of 50 and 200 mg, Cadila Healhtcare said in a BSE filing.

The drug will be produced at the groups formulations manufacturing facility at Baddi (Himachal Pradesh).

Citing IMS data, the company said the estimated sales for Voriconazole tablets is USD 92.8 million as on March 2016.

The Ahmedabad-based group now has more than 100 approvals from the USFDA. Till now, the group has filed over 270 abbreviated new drug applications (ANDAs) since it commenced filing process in 2003-04.

Shares of Cadila Healthcare, the group's listed entity, were trading 0.41 per cent up at Rs 319.45 on BSE in the afternoon session.